文章：

UBE2N抑制可消除肺腺癌的化疗耐药性和转移

UBE2N inhibition abrogates cancer chemoresistance and metastasis in lung adenocarcinoma 

原文发布日期：2025-06-22 

英文摘要：

Chemoresistance and metastasis remain significant challenges in cancer therapy, resulting in treatment failures for cancer patients. Therefore, there is a need to investigate the mechanisms underlying cancer chemoresistance and metastasis, identify novel drug targets, and develop innovative antitumor medications. In this study, we have shown that the ubiquitin conjugating enzyme UBE2N plays a crucial role in promoting chemoresistance and metastasis in lung adenocarcinoma (LUAD) both in vitro and in vivo. Significantly, our study revealed that the natural compound wilforine functions as a potential inhibitor of UBE2N, effectively reversing resistance to cisplatin (CDDP) and inhibiting metastasis of LUAD both in vitro and in vivo. Our findings collectively suggest that UBE2N may have a pivotal role in the development of chemoresistance and metastasis in LUAD, providing a foundation for potential therapeutic strategies in the management of advanced cancer. 

摘要翻译：

化疗耐药和转移仍是癌症治疗中的重大挑战，导致癌症患者治疗失败。因此，有必要研究癌症化疗耐药和转移的机制，确定新的药物靶点，并开发创新的抗肿瘤药物。本研究通过体内外实验证明，泛素结合酶UBE2N在促进肺腺癌（LUAD）化疗耐药和转移中起关键作用。值得注意的是，我们的研究发现天然化合物雷公藤次碱可作为UBE2N的潜在抑制剂，在体外和体内有效逆转对顺铂（CDDP）的耐药性并抑制LUAD转移。我们的研究结果共同表明，UBE2N可能在LUAD化疗耐药和转移的发展中起关键作用，为晚期癌症治疗中的潜在治疗策略提供了基础。

原文链接：

UBE2N inhibition abrogates cancer chemoresistance and metastasis in lung adenocarcinoma